NCT03551249View on ClinicalTrials.gov

Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 26, 2019

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
GliomaGlioblastoma
Interventions
DEVICE

Focused ultrasound (FUS)

FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.

Trial Locations (4)

21201

University of Maryland, Baltimore

22908

University of Virginia, Charlottesville

26506

West Virginia University, Morgantown

02115

Brigham and Women's Hospital, Boston

Sponsors

Lead Sponsor

InSightec
All Listed Sponsors
lead

InSightec

INDUSTRY

NCT03551249 - Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption | Biotech Hunter | Biotech Hunter